| Literature DB >> 35602100 |
Yixin Rui1,2, Sheng Li3, Fei Luan1, Dan Li1, Rong Liu1,2, Nan Zeng1,2.
Abstract
Objectives: Acute kidney injury (AKI) is a loose set of kidney diseases accompanied by a variety of syndromes, which is a serious threat to human life and health. Some alkaloids are derived from various Chinese herbs have been widely concerned in the improvement of AKI. This review provides the research progress of alkaloids in AKI experimental models and discusses the related molecular mechanisms. Key Findings. Alkaloids can protect AKI through various mechanisms including antioxidant stress, improvement of mitochondrial damage, reduction of cell death, induction of autophagy, and inhibition of inflammation. These mechanisms are mainly related to the activation of Nrf2/HO-1 signaling pathway, inhibition of ferroptosis and apoptosis, regulation of PINK1/Parkin pathway, inhibition of TLR4/NF-κB pathway and NLRP3 inflammatory bodies, upregulation of Klotho protein level and so on. In addition, there are a few alkaloids that have certain toxicity on the kidney.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35602100 PMCID: PMC9122709 DOI: 10.1155/2022/2427802
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 7.310
Figure 1Structural formulas for several alkaloids that exert protection in AKI.
Figure 2The classification of classical AKI experimental models. These classical models are classified into three categories, according to clinical causes of AKI: surgery, sepsis, or exposure to nephrotoxic substances.(AKI, acute kidney injury; I/R, ischemia/reperfusion; H/R, hypoxia-oxygen-rich; LPS, lipopolysaccharide; CLP, cecal ligation puncture; GM, gentamicin; CP, cisplatin; DOX, doxorubicin; MTX, methotrexate; As, arsenic; RM, rhabdomyolysis; CM, contrast media).
Pathways involved in the amelioration of AKI by alkaloids.
| Classification | Name | Source | Dose/ | Mechanisms | Models | Clinical etiology (mimic) |
|---|---|---|---|---|---|---|
| Pyrazine alkaloids |
|
| 100 mg/kg, i.p. | Oxidative stress | Rats, GM | Drugs/toxics |
| 50, 100 | Oxidative stress (Nrf2/HO-1) | HK-2 cells, as | Drugs/toxics | |||
| 50, 100 mg/kg, i.p. | Oxidative stress (Nrf2/HO-1), inflammation (TLR4/NF- | Rats, CP | Drugs/toxics | |||
| 40 mg/kg, i.p. | Inflammation (NOD2), apoptosis, autophagy | Rats, I/R | Surgery | |||
| 40 mg/kg, i.p. | Inflammation (NLRP3), apoptosis (caspase-3) | Rats, I/R | Surgery | |||
| 30, 60 mg/kg, i.v. | Apoptosis (caspase-3) | Mice, CLP | Sepsis | |||
| 80 mg/kg, i.p. | Apoptosis (Bax/bcl-2) | Rats, CM | Drugs/toxics | |||
|
| ||||||
| Isoquinoline alkaloids |
|
| 10 | Oxidative stress, mitochondrial damage, apoptosis (Bax/bcl-2/caspase-3) | HK-2 cells, H/R | Surgery |
| 1, 2, 3 mg/kg, i.g. | Oxidative stress (Nrf2/HO-1), apoptosis (caspase-3), inflammation (NF- | Mice, CP | Drugs/toxics | |||
| 20, and 40 mg/kg; p.o. | Oxidative stress, apoptosis, inflammation, mitochondrial damage | Rats, GM | Drugs/toxics | |||
| 20, 40 mg/kg, p.o. | Oxidative stress, apoptosis (Bax/bcl-2/caspase-3), inflammation | Rats, I/R | Surgery | |||
| Nanoparticles, 2, 4 mg/kg, i.v. | Oxidative stress, apoptosis (Bax/bcl-2/caspase-3), | Rats, I/R | Surgery | |||
| 5, 10, 20 mg/kg, i.v. | Oxidative stress | Rats, DOX | Drugs/toxics | |||
| 50 mg/kg, p.o. | Oxidative stress (Nrf2/Keap1), apoptosis(Bax/bcl-2/caspase-3), inflammation (NF- | Rats, MTX | Drugs/toxics | |||
| 5, 10 mg/kg, i.p. | Autophagy (PINK 1/Parkin) | Mice, CP | Drugs/toxics | |||
|
| ||||||
|
|
| 5 mg/kg, i.g. | Apoptosis (Bax/bcl-2/caspase-9/caspase-3), inflammation (TLR4/NF- | LPS, mice | Sepsis | |
|
|
| 20 mg/kg, i.p. | Inflammation(NF- | Mice, I/R | Surgery, sepsis | |
| Indole alkaloids |
|
| 5 mg/kg, i.p. | Oxidative stress (Nrf2), inflammation(NF- | Mice, CP | Drugs/toxics |
|
|
| 5, 25 mg/kg, p.o. | Oxidative stress | Rats, CP | Drugs/toxics | |
|
|
| 10 mg/kg, i.p. | Oxidative stress, inflammation (NF- | Rats, I/R [ | Surgery | |
|
| ||||||
| Pyridine alkaloids |
|
| 150 mg/kg, i.p. | Oxidative stress(Nrf2/HO-1) | Rats, I/R [ | Surgery |
|
| ||||||
| Tropane alkaloids |
|
| 1 mg/kg, i.p. | Oxidative stress, inflammation, apoptosis(caspase-3) | Rats, glycerol [ | Drugs/toxics |
|
| ||||||
|
|
|
| 25, 50 mg/kg, i.g. | Inflammation (TLR4/NF- | Mice, LPS [ | Sepsis |
|
| ||||||
| Organic amine alkaloids |
|
| 50 mg/kg, p.o. | Oxidative stress, inflammation (NF- | Mice, LPS [ | Sepsis |
|
| ||||||
| Aporphine alkaloids |
|
| 30 mg/kg, i.g. | Ferroptosis | Mice, folic acid [ | Drugs/toxics |
Figure 3Some alkaloids inhibit apoptosis in AKI. Some alkaloids can improve AKI by affecting apoptosis in the mitochondrial pathway. (TMP, Tetramethylpyrazine; BBR, berberine; OMT, oxymatrine; MOMP, mitochondrial outer membrane permeability).
Figure 4Some alkaloids inhibit cellular inflammation in AKI. The TLR4/NF-κB and NLRP3 inflammasome pathways may be the primary mechanism by which some alkaloids inhibit inflammation in the treatment of AKI. (TMP, Tetramethylpyrazine; BBR, berberine; Vin, vinpocetine; OMT, oxymatrine).
Figure 5Different targets of alkaloids in AKI. AKI, acute kidney injury; TMP, Tetramethylpyrazine; BBR, berberine; Vin, vinpocetine.